
Topic
Coverage Access
Formulary tiers, utilization management, patient support, and the access layer GoodRx and drug labels do not explain.

Approvals· August 22, 2026 · 19 min read
By Ran Chen#FDA Approval#NDA Approval#Priority Review

Approvals· August 21, 2026 · 19 min read
Pasatru's FOP Approval: What Garetosmab's $1.4M Launch Means vs Sohonos
By Ran Chen#FDA Approval#BLA Approval#Rare Disease

Pricing & Access· August 20, 2026 · 21 min read
Prescription Drug Prices Posted Steepest Drop Since 1963: What CPI Measures

Pricing & Access· August 18, 2026 · 16 min read
DTX401's August 23 PDUFA: Payers Face a Cornstarch-Replacement Gene Therapy
By Ran Chen#Gene Therapy#Rare Disease#Medicaid

Pricing & Access· August 17, 2026 · 25 min read
Medicaid's September 10 Deadline: The Coverage Trade for GENEROUS Pricing
By Ran Chen#Medicaid#Drug Pricing#Payer Policy

Pricing & Access· August 17, 2026 · 25 min read
Tavneos on Formularies as FDA Moves to Withdraw: The Coverage Dilemma

Pricing & Access· August 16, 2026 · 18 min read
Hepatitis C Treatment Access in 2026: Generic Economics, PA, and Sobriety

Specialty· August 16, 2026 · 17 min read
Leqembi IQLIK Launches: Subcutaneous Lecanemab Moves to Specialty Pharmacy

Policy· August 16, 2026 · 15 min read
Ten PBMs Commit to TrumpRx Cash Prices in Real-Time Tools: The Policy Ledger
By Ran Chen#PBM#Payer Policy#Formulary Strategy

Specialty· August 15, 2026 · 25 min read
Kidney Transplant Immunosuppression: Part B-ID Cliff, Tacrolimus, & Access
By Ran Chen#Nephrology#Medicare Part B#Coverage Access